Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). The Company is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.
Type
Public
HQ
Canton, US
Founded
2002
Size (employees)
234 (est)
Collegium Pharmaceutical was founded in 2002 and is headquartered in Canton, US
Report incorrect company information

Key People/Management at Collegium Pharmaceutical

Michael Heffernan

Michael Heffernan

Co - Founder, President & CEO
Michael Heffernan

Michael Heffernan

Co-Founder, President, CEO
Heow Tan

Heow Tan

Vice President of Technical Operations

Collegium Pharmaceutical Office Locations

Collegium Pharmaceutical has an office in Canton
Canton, US (HQ)
800 780 Dedham St
Show all (1)
Report incorrect company information

Collegium Pharmaceutical Financials and Metrics

Collegium Pharmaceutical Financials

USD

Net income (Q1, 2018)

(18.7 m)

EBIT (Q1, 2018)

(13.2 m)

Market capitalization (22-Jun-2018)

879.6 m

Closing share price (22-Jun-2018)

26.6

Cash (31-Mar-2018)

128.2 m
Collegium Pharmaceutical's current market capitalization is $879.6 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

18.9 m80.6 m92.8 m

R&D expense

8 m14.9 m8.6 m

Operating expense total

26.9 m95.6 m103.9 m

EBIT

(26.9 m)(94.1 m)(75.4 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q1, 2017Q2, 2017Q1, 2018

General and administrative expense

2.9 m5.9 m11.5 m20.2 m22.8 m22.1 m31.6 m

R&D expense

1.6 m3.4 m4.1 m4.3 m2.1 m2.2 m2.3 m

Operating expense total

4.6 m9.3 m15.6 m24.5 m25.3 m24.8 m77 m

EBIT

(4.6 m)(9.3 m)(15.6 m)(24.5 m)(23.2 m)(21.3 m)(13.2 m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

95.7 m153.2 m118.7 m

Accounts Receivable

2.1 m10 m

Inventories

1.2 m1.9 m1.8 m

Current Assets

96.9 m158.6 m133.5 m
Quarterly
USDQ3, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

105.5 m110.7 m91 m129.6 m111.2 m128.2 m

Accounts Receivable

3 m1.7 m3.3 m4.9 m66 m

Inventories

1.2 m1.6 m1.5 m1.5 m7.9 m

Current Assets

106.3 m116.5 m95.4 m136.5 m120.6 m207.7 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(27.3 m)(94.2 m)(74.9 m)

Depreciation and Amortization

171 k655 k594 k

Inventories

(659 k)(1.3 m)(497 k)

Accounts Payable

1.3 m5.6 m(3.4 m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(4.7 m)(17.7 m)(15.7 m)(24.5 m)(23.1 m)(44.2 m)(18.7 m)

Depreciation and Amortization

130 k208 k332 k482 k

Inventories

1.2 m1.6 m(179 k)(204 k)134 k

Accounts Payable

2.2 m962 k6.2 m6.1 m9 m(2.3 m)(3.5 m)3.7 m
USDY, 2018

Financial Leverage

7.7 x
Show all financial metrics
Report incorrect company information

Collegium Pharmaceutical News and Updates

Report incorrect company information